Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Adaptive Biotechnologies Corporation    ADPT

ADAPTIVE BIOTECHNOLOGIES CORPORATION

(ADPT)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Summary
  • The company has poor fundamentals for a short-term investment strategy.
Strengths
  • The share is getting closer to its long-term support in weekly data, at USD 35.79, which offers good timing for buyers.
  • The close medium term support offers good timing for purchasing the stock.
  • The prospective high growth for the next fiscal years is among the main assets of the company
  • Thanks to a sound financial situation, the firm has significant leeway for investment.
  • Analysts covering this company mostly recommend stock overweighting or purchase.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
  • The company has insufficient levels of profitability.
  • Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
  • The company's earnings releases usually do not meet expectations.
  • The company's "enterprise value to sales" ratio is among the highest in the world.
  • The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
  • For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
  • For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
  • For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
Sector Bio Diagnostics & Testing
1st jan.Capitalisation (M$)Investor Rating
ADAPTIVE BIOTECHNOLOGIES CO..-31.64%5 627
EXACT SCIENCES CORPORATION-3.01%21 228
GUARDANT HEALTH, INC.21.95%15 784
BGI GENOMICS CO., LTD.-5.19%8 067
INVITAE CORPORATION-9.11%7 473
IOVANCE BIOTHERAPEUTICS, IN..-34.94%4 437
-
SEEGENE, INC.-13.47%3 925
CAREDX, INC-0.97%3 718
VERACYTE, INC.7.42%3 522
ASPIRA WOMEN'S HEALTH INC.-7.15%696
-
Q-LINEA AB (PUBL)-10.00%483
BIOVICA INTERNATIONAL AB (P..-16.99%141
ANPAC BIO-MEDICAL SCIENCE C..8.87%69
LYSOGENE6.04%55
SPAGO NANOMEDICAL AB (PUBL)0.00%36
THERADIAG-11.97%23
More Results
Financials (USD)
Sales 2021 150 M - -
Net income 2021 -237 M - -
Net cash 2021 303 M - -
P/E ratio 2021 -23,3x
Yield 2021 -
Capitalization 5 627 M 5 627 M -
EV / Sales 2021 35,5x
EV / Sales 2022 24,6x
Nbr of Employees 622
Free-Float 92,6%
Upcoming event on ADAPTIVE BIOTECHNOLOGIES CORPORATION
05/18/21
Surperformance Ratings©
  Help  
Fundamental ratings
Overall rating
Trading Rating
Investor Rating
Growth (Revenue)
Valuation
Finances
Profitability
Earnings quality
Business Predictability
P/E ratio -
Potential
Yield -
Consensus
7 days EPS revision
4 months EPS revision
1 year EPS revision
4 months Revenue revision
1 year Revenue revision
Technical ratings
Short Term Timing
Middle Term Timing
Long Term Timing
RSI
Bollinger Spread
Unusual Volumes